---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114413"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T07:41:58.569511+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel Q3 2022 net loss $19.0M, TAVALISSE sales up 20%, workforce cut 16%

## Summary
- Q3 net loss $19.0M ($0.11/sh) vs $21.0M loss a year ago; total revenue $22.4M.
- TAVALISSE net product sales $19.2M, up 20% YoY from $16.0M.
- Reduced workforce by 16% (30 positions) in development and administration.
- Olutasidenib NDA under FDA review with PDUFA date Feb 15, 2023; preparations for launch.
- FOCUS COVID-19 Phase 3 trial missed primary endpoint (p=0.0603); no sNDA for wAIHA.

## SEC filing metadata
- accession: 0001104659-22-114413
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/tm2229578d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114413
- JSON: https://secwatch.observer/filing/0001104659-22-114413.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114413.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2022 results: revenue $69.0 million, net income net loss of $60.0 million, EPS ($0.35) per basic and diluted share.
  - Period: nine months ended September 30, 2022
  - Revenue: $69.0 million
  - Net income: net loss of $60.0 million
  - EPS: ($0.35) per basic and diluted share
  - Result: reported results
  source text: For the nine months ended September 30, 2022, Rigel reported a net loss of $60.0 million, or $0.35 per basic and diluted share, compared to a net income of $4.7 million, or $0.03 per basic and diluted share, for the same period of 2021. For the nine months ended September 30, 2022, total revenues were $69.0 million, consisting of $53.9 million in TAVALISSE net product sales, $12.5 million in contract revenues from collaborations and $2.5 million in government contract revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $22.4 million, net income net loss of $19.0 million, EPS ($0.11) per basic and diluted share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $22.4 million
  - Net income: net loss of $19.0 million
  - EPS: ($0.11) per basic and diluted share
  - Result: reported results
  source text: For the third quarter of 2022, Rigel reported a net loss of $19.0 million, or $0.11 per basic and diluted share, compared to a net loss of $21.0 million, or $0.12 per basic and diluted share, for the same period of 2021. For the third quarter of 2022, total revenues were $22.4 million, consisting of $19.2 million in TAVALISSE net product sales, $0.7 million in contract revenues from collaborations and $2.5 million in government contract revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm
- Governance Changes
  RIGEL PHARMACEUTICALS INC: Amended and restated bylaws effective October 31, 2022 with revisions to stockholder proposal disclosures, meeting conduct, and exclusive forum provisions (effective 2022-10-31).
  - Change: bylaw amendment
  - Effective: 2022-10-31
  source text: On October 31, 2022, the Board of Directors of the Company (the "Board") approved the second amendment and restatement of the Bylaws of the Company (the "Amended and Restated Bylaws"). The Amended and Restated Bylaws are effective as of October 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm
- Material Agreements
  RIGEL PHARMACEUTICALS INC entered into sublease agreement with Atara Biotherapeutics, Inc. valued at approximately $1.8 million (based on 13,670 rentable square feet, term through May 24, 2025) (effective 2022-10-28).
  - Action: entry
  - Agreement: lease
  - Counterparty: Atara Biotherapeutics, Inc.
  - Value: approximately $1.8 million (based on 13,670 rentable square feet, term through May 24, 2025)
  - Effective: 2022-10-28
  source text: On October 28, 2022, Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”) entered into a sublease agreement with Atara Biotherapeutics, Inc. to sublease approximately 13,670 rentable square feet of office space located in South San Francisco, California.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.